Introduction
Chronic graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in survivors of allogeneic stem cell transplantation (allo-SCT). 1 Chronic GVHD shows variable clinical manifestations similar to those in autoimmune disorders and may involve diverse tissues, including the skin, eyes, oral mucosa, liver, lungs, and gut. 2 Primary treatment consists of steroids alone or in combination with calcineurin inhibitors such as cyclosporine or tacrolimus, extending for several months and often years. 3, 4 Despite these efforts, many patients respond poorly to treatment, resulting in late mortality. 4, 5 Furthermore, chronic GVHD and its prolonged treatment may seriously degrade a patient's quality of life (QOL). 6 Available treatments are few, however, and no consensus currently exists regarding the best treatment for steroid-refractory chronic GVHD. There is an urgent need for new choices in effective therapy.
Although we do not fully understand the pathogenesis of chronic GVHD, studies suggest that B cells, as well as donor-derived T cells, may be involved. Thus, alloantibody to Y chromosome-associated minor histocompatibility antigens correlate with chronic GVHD in sex-mismatched allo-SCT, and donor-derived B cells have been shown to be required to induce chronic GVHD in a murine model. 7, 8 Elevated levels of BAFF (B cell-activating factor of the tumor necrosis factor family) are also correlated with the occurrence and severity of chronic GVHD. 9, 10 Thus, B cells may present a therapeutic target in the treatment of chronic GVHD, especially in the steroid-refractory cases.
Rituximab is a chimeric monoclonal antibody that binds to CD20 antigens on the surfaces of B cells. Although widely used to treat B-cell lymphomas, it has recently been shown to be effective in steroid-refractory chronic GVHD; a meta-analysis found a response rate of up to 70%. 11 Most previous reports, however, concerned single cases or retrospective analyses of 6 small series of patients. [12] [13] [14] [15] All but one of four prospective studies included only three to seven patients. [16] [17] [18] [19] Furthermore, most previous studies classified chronic GVHD as limited or extensive disease according to a historical definition, and response criteria varied among the studies. As a result, prospective and retrospective studies have produced variable response rates and organ-specific responses. 11 To standardize the criteria for diagnosis and response in chronic GVHD, the National Institutes of Health (NIH) Consensus Development Project released new criteria for clinical trials in this disease. 20, 21 Up to now, only one small prospective study of seven patients has used these NIH criteria, 19 and none has addressed the QOL. We therefore performed this phase II study to evaluate both the effectiveness of rituximab (i.e., the clinical response) and the QOLs in patients with steroid-refractory chronic GVHD, based on the NIH criteria for clinical trials. 20, 21 7
Design and methods

Study design
This study was an open-label multicenter prospective phase II study to evaluate the efficacy of rituximab in terms of response to treatment, improvement in quality of life and discontinuation of steroids. The eligible subjects were patients with steroid-refractory chronic GVHD that required treatment. Thus, all patients had at least one diagnostic sign of chronic GVHD or at least one distinctive manifestation confirmed by biopsy or other laboratory tests according to the criteria for clinical trials in chronic GVHD released by the NIH Consensus Development Project. 20 All patients also had at least a moderate score for chronic GVHD, defined as a maximum score of at least two in any affected organ or a score of one in all affected organs in the global scoring system for chronic GVHD. 20 Steroid-refractory chronic GVHD was defined as chronic GVHD with sustained severity during the last full month during which the patients had received the equivalent of prednisone 0.5 mg/kg per day or 1 mg/kg every other day. Concomitant use of other immunosuppressive agents was permitted except for extracorporeal phototherapy or other experimental treatments. We excluded patients who had received donor lymphocyte infusions within 100 days preceding the trial.
Patients who had a serious comorbidity such as active infection or a life expectancy of less than one month were also not eligible to participate. The institutional review board at each participating center approved this study, and all patients provided written informed consent.
This trial was registered at www.clinicaltrials.gov as #NCT00472225.
Treatment and response evaluation
The treatment consisted of weekly intravenous (IV) infusions of rituximab 375 mg/m 2 for four weeks followed by monthly rituximab for four months ( Figure 1A ). Baseline evaluations were performed within seven days before enrollment, and the first treatment response was 8 evaluated after completion of the weekly rituximab infusions (D29, Figure 1A 
Response definition and steroid tapering
We used the criteria from the NIH Consensus Development Project to define a response. 21 Complete response (CR) was defined as the resolution of all signs and symptoms associated with chronic GVHD. Partial response (PR) was defined as a clinical score reduction of at least one point in one or more affected organs, with no evidence of deterioration in any organ. The objective response therefore included both CR and PR. Progressive disease (PD) was defined as a clinical score increase of at least one point in one or more organs or occurrence of any new symptoms or signs of chronic GVHD. We defined the lack of response without the requirement for additional immunosuppressive therapy as no response (NR). Based on the objective response, investigators could reduce the steroid dosage. Subjects with NR or PD received a fixed or increased steroid dosage through the next response evaluation. Regimens for immunosuppressants other than steroids were similarly modified.
Quality of life (QOL) measurement
For QOL assessment, the SF-36 questionnaire version 2.0 (QualityMetric, RI, USA) was used scores using the "SF-36 Physical and Mental Health Summary Scales". 22 The score was normalized to that of healthy people, set at 50 (+/-10).
Sample collection and measurement of serum BAFF
Serum samples were obtained during the study period (Baseline, D57, and D365) and were 
Sample size calculation and statistical analysis
A previous study with weekly administration of rituximab showed a 70% overall response rate in steroid-refractory chronic GVHD. 18 Thus, if our treatment regimen of weekly rituximab and monthly rituximab maintenance failed to show more than a 50% overall response, this treatment would be deemed ineffective. A response rate greater than 70%, however, could indicate effectiveness in the treatment of steroid-refractory chronic GVHD.
Based upon the above assumption, we designed this trial using Simon's minimax two-stage testing procedure. 23 Assuming a target level of interest, p1 = 0.70, and a lower activity level 10 of p0 = 0.50, 23 patients needed to be accrued, and if ≥ 13 objective responses were observed, the trial would be continued to 37 patients. This design provided a probability of ≤ 0.05 of accepting a treatment worse than p0 and a probability of ≤ 0.20 for rejecting a treatment better than p1.
We 
Results
Characteristics of patients and allo-SCT
This study included 37 patients ranging in age from 8 to 57 years, with a median of 29 years (Table 1) . Approximately one-third of these patients (32.4%) showed a poor performance status (ECOG grade 2/3) at the time of entry. Although we excluded patients with serious comorbidities, we included those with diabetes mellitus and previous tuberculosis. There were no patients having hepatitis B virus antigen, antibody against hepatitis C virus, and human immunodeficiency virus. All patients received allo-SCT, and two patients underwent a second allo-SCT. Myeloablative conditioning was the dominant procedure (78.4%, Table 1 ), and cells of unrelated donors were more commonly used than cells of the sibling donors. Bone marrow was the main source of stem cells, and mismatches of ABO type and sex occurred more frequently than did matched cases.
Characteristics of steroid-refractory chronic GVHD
All patients had at least moderate chronic GVHD, with a median duration of 5.2 months (range 2.2-25.5 months, Table 1 ) before entry to the study. More than one-half of patients had a previous history of acute GVHD (56.8%). The disease involved diverse organs from skin to gut (Table 1) . Three patients had other immune-mediated disorders such as two cases with hemolytic anemia and one proteinuria ( Table 1) . The majority of patients had multiple-organ involvement, with a median of 2.78 (range 1-5) organs per person. At the time of enrollment, all patients received steroid with or without other immunosuppressive agents, and the median duration of steroid treatment was 1.8 months (range 1-28 months).
Response and steroid discontinuation
We assessed response to treatment at designated time points during the one-year study period ( Figure 1A ). Some patients maintained their initial response, while in others, the initial 12 response diminished during follow-up. In the calculation of maximum response for the study period, eight patients showed CR and 24 patients showed PR ( Table 2 ). The median time to maximal response was day 29 ( Figure 1B , range from day 0 to day 252). Overall, 21 patients maintained their response until the final visit. These patients (21/37, or 56.8%) then discontinued steroids or reduced their dosage (Table 2) . Because the median number of involved organs was 2.78 (range 1-5) organs per person, the number of evaluable organ was larger than the number of patients. Evaluation of response according to the organs involved showed that lesions in the musculoskeletal system, skin and oral cavity responded better than those in the eye, liver and gut (Table 3 ). Only one patient showed a PR (9.1%, 1/11, Table 3) in the lung, the organ least responsive to treatment. Immune-mediated manifestations such as hemolytic anemia responded well to rituximab (Table 3) . Baseline characteristics of patients, including duration of chronic GVHD, did not influence the response to rituximab (P > 0.05, data not shown). However, all patients 15 years old (n = 8) showed an objective response, and seven of these maintained their responses. Specific features of the allo-SCT, such as stem cell source, HLA matching, or the type of conditioning, were not associated with response (P > 0.05, data not shown).
Mortality and drop-out
Five patients did not respond to treatment, so they dropped out from the study (#18, 21, 24, 29, 32). Of these, two patients (#29, 32) dropped out after day 29 because of suspected pulmonary tuberculosis and infectious colitis, respectively. Tests showed, however, that they did not have those complications, and they both recovered. Another patient (#18) with NR withdrew his consent after day 85. The other two patients (#21, 24) died of pneumonia (Table 2) . On the other hand, six patients showed disease progression after they achieved PR (#6, 9, 10, 13, 15, 36, Table 2 ). Among these six patients, two patients (#6, 9) died of pneumonia and sepsis during follow-up, and one patient with lung involvement (bronchilolitis obliterance) died of (Table 2 ). Considering these infectious complications or relapses during the study, we performed the competing risk analysis for response to estimate the cumulative incidence rates.
As a result, the cumulative incidence rate of response was 89.2% at 254 days while that of events including infection-related death and relapse was 10.8% at 254 days.
Quality of life
We assessed the QOL at three designated points (baseline, day 56 and day 365). With a score of 50 assumed to represent that of a normal healthy person, the baseline scores in all domains
were below 50 at the study entry in the ITT and PP analyses (Figure 2 ). However, patients reported increased scores in six domains (RP, BP, GH, SF, RE and MH), although only the RP and BP effects showed statistical significance ( Figure 2A , P < 0.05). This finding became more prominent in the PP analysis, which included only patients with complete follow-up through day 365 ( Figure 2B ). Because all of these patients showed an objective response, their final score at day 365 approached 50 in several domains, although these changes were not significant. However, scores in some domains, especially the physical domains including PF, RP, and BP, decreased. Thus, the score for PCS decreased as the study progressed, while the MCS score did not (Figure 2 ).
Serum BAFF and immune globulins
14
The median baseline level of serum BAFF was 1225 pg/mL (range 129-8188pg/mL), higher than the median reported for normal healthy Asian people (range 780-861 pg/mL).
24, 25
Generally, we found that patients with a serum BAFF lower than 1000 pg/mL showed better outcomes. Thus, 78.5% (11/14) of those with lower levels maintained their response at day 365, while 50% (9/18) of those with higher levels showed PD or complications, although this effect was not statistically significant (P = 0.147). Serum BAFF increased continuously, with an inverse correlation to the sustained treatment-related decrease in immune globulins ( Figure   3 Our study is currently the largest one to evaluate the response of steroid-refractory chronic GVHD to rituximab using the NIH criteria. Unlike previous prospective studies which recruited only adults, our group of 37 patients included eight patients who were 15 years old.
The previous studies used a uniform treatment schedule consisting of a weekly rituximab infusion for four weeks, with an additional four weeks of this treatment for patients with no response or incomplete response at the first evaluation. 16, 18 We treated our group initially with the same schedule, and at the end of an induction phase (Day 29), observed an objective response in 26 patients (70.3%, 26/37). After that, we proceeded to the monthly administration of rituximab for four months as a maintenance treatment. During or after this phase, six patients who did not respond to the weekly rituximab showed a delayed response (Table 2) . Thus, the objective response rate based on the maximum response of each patient was 86.5% (32/37, Table 2 ). However, only 22 patients completed the study as planned; 15 patients dropped out when their disease progressed or when infection developed. The final overall response rate at one year was therefore 56.8% (21/37), and these patients were able to discontinue steroids or reduce their dosage (Table 2) . When these infection-related deaths and relapses considered as competing risks, the cumulative incidence rate of response was 89.2%
at 254 days.
The musculoskeletal and dermal manifestations of GVHD responded better than did those in the eye, liver and gut (Table 3) , consistent with results of previous reports. 13, 14, 17, 18 In our study, however, oral cavity lesions showed better responses than those previously reported.
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This may reflect the shorter duration of chronic GVHD in our study (median 5.2 months) than in the previous ones (median duration 14-37 months), because long-standing disease might result in destruction of target tissues such as the salivary glands. 14, 16, 18 As in previous reports, lungs showed the least responsiveness, while immune-mediated manifestations such as hemolytic anemia responded well to rituximab. Although we found no clinical parameters that predicted the response to rituximab, the patients 15 years old responded better than did those > 15 years; seven young patients maintained their response until their last visit (7/8, 87.5%); and 14 older patients maintained their response through the end of the planned study period (14/29, 48.3%).
In a recent review of QOL assessments, the majority of studies suggested that more than 60% of patients reported good to excellent QOL in years 1 to 4 after allo-SCT. 28 All of our patients, however, showed scores below the average for normal healthy people in all domains of the baseline QOL evaluation. Moreover, despite clinical improvement in the majority of patients after treatment, the QOL did not increase significantly, although it showed a positive trend ( Figure 2 ). This finding suggests that steroid-refractory chronic GVHD may seriously impair the QOL, even after the resolution of symptoms. Active behavioral interventions as well as medical treatments may be required to improve and maintain the QOL.
Although we observed a delayed response during or after the maintenance phase, disease progression also occurred in this later time. Moreover, eight patients died of infectious complications, including pneumonia and sepsis (Table 2 ). Because all of these patients received both steroids and other immunosuppressive agents throughout the study, we could not demonstrate a causal relationship between rituximab and infection. However, serum immunoglobulins remained suppressed below the normal range until the final visit (Day 365, In our study, patients with a serum BAFF higher than 1000 pg/mL showed treatment failure more frequently, e.g., as disease progression, than did those with lower levels. Although this effect was not significant (P = 0.147), it is consistent with a role of BAFF in the occurrence and severity of chronic GVHD. 9, 10 However, serum BAFF increased during the study period, with an inverse correlation to the decrease in immune globulins (Figure 3 ). This decrease in immune globulins and increase in the level of serum BAFF may be related to the depletion of B-cells because rituximab can deplete normal B cells. Therefore, the serum level of BAFF 18 during treatment may not provide any additional value predicting the response or activity of chronic GVHD although the pre-treatment level of BAFF lower than 1000 pg/mL seemed to be associated with the likelihood of response to rituximab. However, this association of pretreatment level of serum BAFF with the response to rituximab was not statistically significant.
It might relate with the number of patients in our study. Thus, it may be worth extending the study to include larger patient numbers to confirm the association of serum BAFF with the treatment response and disease activity of chronic GVHD.
In summary, we report here the largest multicenter study to date to evaluate the efficacy of rituximab using the NIH criteria for diagnosis and response measurement for clinical trials in steroid-refractory chronic GVHD. 20, 21 We found that rituximab may reduce clinical manifestations, permit steroid discontinuation, and improve QOL in patients with this disease.
However, patients may require prophylactic treatment for infections related to B-cell depletion.
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